Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 1997

View Archived Issues

New immunosuppressants in the pipeline at Merck & Co.

IL-5 receptor ligands reported by Glaxo Wellcome

New antifungals disclosed by Schering-Plough

New photodynamic agents reported by Novartis

Improved method for vWF purification developed by Bayer

HMR discloses new anti-HIV agents

UPSA claims new COX-2 inhibitors for inflammation, pain and other disorders

New orally active antihypertensive compounds prepared at Rotta

Cytogen updates stockholders

Potent and selective AMPA antagonist from Roche

FR-208419: a new dual CCK-A and CCK-B/gastrin receptor antagonist

Banyu searches for potent, orally bioavailable FXa inhibitors

Favorable phase III trial results reported for HER2 monoclonal antibody

Cambridge Antibody Technology: FY 1997 highlights

FDA deems Provigil approvable

Raxar --new once-daily fluoroquinolone-- now available in U.S.

Commencement of phase II trials of LiquiVent for adult ARDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...